

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MacLEAN et al

Serial No. 08/776,350

Filed: April 18, 1997

For: TREATMENT OF CANCER USING HSV MUTANT



Atty. Ref.: 620-73

Group: 1642

Examiner: Ungar

24/8  
w/ 2/2/01  
RECEIVED

JAN 31 2001

TECH CENTER 1600/2800

January 22, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

AMENDMENT

Responsive to the Official Action dated September 22, 2000, entry and consideration of the following amendments and remarks are requested; the period for response having been extended up to and including January 22, 2001, by submission of the requisite petition and fee, attached.

IN THE SPECIFICATION

Amend the specification as follows.

Page 4, lines 1-6, delete "mutant virus ... However, this", and insert the following therefor: --mutant virus called 1716 that has a 759 bp deletion in  $\gamma$ 34.5(16).

The construction of mutant virus 1716 is described in U.S. Patent No. 6,040,169, the entire contents of which is incorporated herein by reference. The mutant virus called 1716 has been deposited with the ECACC PHLS Center for Applied Microbiology and Research, Porton Down, Salisbury, Wits. SP4 PJG, UK, on January 28, 1992,